240 related articles for article (PubMed ID: 26363314)
1. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
4. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
7. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
8. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
9. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
10. Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Souchet B; Duchon A; Gu Y; Dairou J; Chevalier C; Daubigney F; Nalesso V; Créau N; Yu Y; Janel N; Herault Y; Delabar JM
Sci Rep; 2019 Mar; 9(1):3914. PubMed ID: 30850713
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome.
Rueda N; Flórez J; Martínez-Cué C
Behav Brain Res; 2008 Apr; 188(2):355-67. PubMed ID: 18178265
[TBL] [Abstract][Full Text] [Related]
12. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
[TBL] [Abstract][Full Text] [Related]
13. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
[TBL] [Abstract][Full Text] [Related]
14. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
[TBL] [Abstract][Full Text] [Related]
15. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.
Neumann F; Gourdain S; Albac C; Dekker AD; Bui LC; Dairou J; Schmitz-Afonso I; Hue N; Rodrigues-Lima F; Delabar JM; Potier MC; Le Caër JP; Touboul D; Delatour B; Cariou K; Dodd RH
Sci Rep; 2018 Feb; 8(1):2859. PubMed ID: 29434250
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
[TBL] [Abstract][Full Text] [Related]
17. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
[TBL] [Abstract][Full Text] [Related]
18. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
20. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome.
Shichiri M; Yoshida Y; Ishida N; Hagihara Y; Iwahashi H; Tamai H; Niki E
Free Radic Biol Med; 2011 Jun; 50(12):1801-11. PubMed ID: 21447382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
